CTLA4 and neoplasm: Ipilimumab is an IgG1 monoclonal antibody against the extracellular domain of CTLA-4 that prevents T cell suppression by inhibitory immune checkpoints, resulting in a potent anti-tumour effect by enhancing effector cells and inhibiting regulatory activity of T cells [86,102].